Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 8/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.42 |
| ▸ | TAF1 | P21675 | 2/20 | 0.42 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935121 | 0.94 | MTOR (0.47) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL18015070 | 0.94 | MTOR (0.47) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4208810 | 0.93 | MTOR (0.55) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3932814 | 0.91 | MTOR (0.54) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3929181 | 0.89 | PIK3CA (0.59) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL18013707 | 0.89 | PIK3CA (0.59) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4210486 | 0.88 | MTOR (0.50) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4205053 | 0.87 | MTOR (0.55) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3938221 | 0.87 | MTOR (0.55) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3935684 | 0.87 | MTOR (0.56) | MTORPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022731-A1 | 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022731-A1 | 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS | RET, MECP2, RB1 | MTOR 940/4885PIK3CA 73/4885PIK3CD 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.